Curcumin showed poor oral bioavailability. Two patients showed relevant clinical activity: one patient showed stable disease for more than 1.5 years; patient showed brief but consistent tumor regression (73%) accompanied by increased levels of serum cytokines (IL6, IL8, IL10, and IL1) in the range of 4-35-fold. Curcumin reduced the expression of NF-κB, COX-2, and pSTAT3 in mononuclear blood cells from patients. This evidence concerns the gene PTGS2 and neoplasm.